===
EQS-News: SARTORIUS AG / Key word(s): Personnel
Sartorius AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office - Supervisory
Board expresses great regret (news with additional features)
2024-07-02 / 10:53 CET/CEST
The issuer is solely responsible for the content of this announcement.

Göttingen, July 2, 2024
Sartorius AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office - Supervisory
Board expresses great regret
The long-standing CEO of Sartorius AG, Dr. Joachim Kreuzburg, has informed the company's Supervisory Board that after
more than 20 years as CEO of the company, he will not be seeking another extension of his current contract when it
expires in November 2025. The Supervisory Board has taken note of Kreuzburg's decision with great regret.
Kreuzburg has been at the helm of the company since 2003. After joining Sartorius AG in 1999, he was appointed to the
Executive Board in 2002 at the age of 37 and became Chairman a few months later. During this time, Sartorius' sales
revenue increased more than 7-fold to around 3.4 billion euros and profits more than 26-fold to around 1 billion euros,
the number of employees quadrupled to over 14,000 while the Group's stock market valuation increased from just over 90
million euros to more than 17 billion euros.
The Chairman of the Supervisory Board of Sartorius AG, Dr. Lothar Kappich, said: "Sartorius owes Joachim Kreuzburg an
extraordinary amount. With his dynamic entrepreneurial qualities, he has transformed the company into an
internationally leading and particularly profitable life science group, expanded the technology and product portfolio
enormously and built up an outstanding team. We very much regret his decision. At the same time, we would like to thank
him for informing us of his decision at an early stage and for continuing to be available to Sartorius until November
2025. The Supervisory Board will now initiate a succession process in an orderly and careful manner. I look forward to
continuing to work so closely and well with Joachim Kreuzburg for another one and a half years until his departure."
Kreuzburg said: "After so many years at the helm of this special company, I would like to have more space and time for
new topics and projects in the future. For the upcoming phase of my life, I am ruling out taking on an executive top
role, while I will continue to be involved in my mandates in business and science and will also engage in further
business activities, especially in such innovation-driven sectors as biotechnology and medicine. After a phase of
extraordinary growth, the entire life science industry is facing temporary challenges in the current "post-pandemic
phase", while the prospects for the future remain excellent. The trough has been passed and I will continue to fully
focus on Sartorius over the next year and a half and, together with my team, will work with all my energy to ensure
that the company continues to develop more innovatively, faster and more profitably than the competition. At the same
time, it was important to me to inform the Supervisory Board of my plans at an early point so that they can prepare for
my succession without time pressure."
A profile of Sartorius
Sartorius (XETRA: SRT3 | STR) is a leading international partner of life sciences research and the biopharmaceutical
industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services division focuses
on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as
academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on
single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely,
rapidly, and economically. The company, based in Göttingen, Germany, has a strong global reach with around
60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of
complementary technologies. In 2023, the company generated sales revenue of around 3.4 billion euros. Currently, around
14,600 employees are working for customers around the globe.
Visit our newsroom and follow Sartorius on LinkedIn.
Contact
Petra Kirchhoff
Head of Corporate Communications & Investor Relations
+49 (0)551.308.1686
petra.kirchhoff@sartorius.com

Additional features:
File: 240702_Media Release_SAG_Contract CEO_en (1)
2024-07-02 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com  
Language:     English 
Company:      SARTORIUS AG 

Otto-Brenner-Straße 20
37079 Göttingen
Germany

Phone:        +49.(0)551-308.0 
Fax:          +49.(0)551-308.3289 
E-mail:       info@sartorius.com 
Internet:     www.sartorius.com 
ISIN:         DE0007165607, DE0007165631 
WKN:          716560 , 716563 
Indices:      DAX, TecDAX 
Listed:       Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, 

Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1937941

End of News EQS News Service
===
1937941 2024-07-02 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1937941&application_name=news&site_id=dow_jones%7e%7e%7ef1066a31-ca00-4e1a-b0a4-374bd7d0face

END) Dow Jones Newswires

July 02, 2024 04:53 ET (08:53 GMT)